These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 24283819)

  • 1. SEPs N30 amplitude in Parkinson's disease and in pharmacologically induced rigidity: relationship with the clinical status.
    Stanzione P; Traversa R; Pierantozzi M; Semprini R; Loberti M; Peppe A; Santilli AM; Bernardi G
    Eur J Neurol; 1997 Jan; 4(1):24-38. PubMed ID: 24283819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Curariform peripheral block of muscular tone selectively increases precentral N30 somatosensory evoked potentials component. A pharmacological study carried out on healthy subjects and parkinsonian syndromes.
    Pierantozzi M; Sabato AF; Leonardis F; Marciani MG; Cicardi C; Giacomini P; Bernardi G; Stanzione P
    Exp Brain Res; 2000 Aug; 133(3):368-76. PubMed ID: 10958527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Somatosensory evoked potentials at rest and during movement in Parkinson's disease: evidence for a specific apomorphine effect on the frontal N30 wave.
    Cheron G; Piette T; Thiriaux A; Jacquy J; Godaux E
    Electroencephalogr Clin Neurophysiol; 1994 Nov; 92(6):491-501. PubMed ID: 7527767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N30 wave amplitude of somatosensory evoked potentials from median nerve in Parkinson's disease: a pharmacological study.
    Traversa R; Pierantozzi M; Semprini R; Loberti M; Cicardi MC; Bassi A; Stanzione P
    J Neural Transm Suppl; 1995; 45():177-85. PubMed ID: 8748624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N30 Somatosensory Evoked Potential Is Negatively Correlated with Motor Function in Parkinson's Disease.
    Kang SY; Ma HI
    J Mov Disord; 2016 Jan; 9(1):35-9. PubMed ID: 26828214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in the amplitude of the N30 frontal component of SEPs during apomorphine test in parkinsonian patients.
    de Mari M; Margari L; Lamberti P; Iliceto G; Ferrari E
    J Neural Transm Suppl; 1995; 45():171-6. PubMed ID: 8748623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatosensory evoked potentials and dopaminergic responsiveness to apomorphine and levodopa in parkinsonian patients.
    Miranda M; Castillo JL; Araya F
    Behav Neurol; 1996; 9(3):149-53. PubMed ID: 24487514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormality of N30 somatosensory evoked potentials in Parkinson's disease: a multidisciplinary approach.
    Bostantjopoulou S; Katsarou Z; Zafiriou D; Gerasimou G; Alevriadou A; Georgiadis G; Kiosseoglou G; Kazis A
    Neurophysiol Clin; 2000 Dec; 30(6):368-76. PubMed ID: 11191929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The abnormality of N30 somatosensory evoked potential in idiopathic Parkinson's disease is unrelated to disease stage or clinical scores and insensitive to dopamine manipulations.
    Onofrj M; Fulgente T; Malatesta G; Ferracci F; Thomas A; Curatola L; Bollettini F; Ragno M
    Mov Disord; 1995 Jan; 10(1):71-80. PubMed ID: 7885358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormalities of somatosensory evoked potentials in spasmodic torticollis.
    Mazzini L; Zaccala M; Balzarini C
    Mov Disord; 1994 Jul; 9(4):426-30. PubMed ID: 7969209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Somatosensory evoked potentials and symptomatic response to dopaminergic drugs in Parkinson's disease].
    Castillo JL; Miranda CM; Araya F; Sáez D
    Rev Med Chil; 1996 Mar; 124(3):301-6. PubMed ID: 9008941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The frontal N30 component of the median-derived SEP in patients with predominantly unilateral Parkinson's disease.
    Garcia PA; Aminoff MJ; Goodin DS
    Neurology; 1995 May; 45(5):989-92. PubMed ID: 7746421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. N30 somatosensory evoked potentials in patients with unilateral Parkinson's disease.
    Drory VE; Inzelberg R; Groozman GB; Korczyn AD
    Acta Neurol Scand; 1998 Feb; 97(2):73-6. PubMed ID: 9517855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship in gating effects between short-latency and long-latency somatosensory-evoked potentials.
    Nakata H; Sakamoto K; Yumoto M; Kakigi R
    Neuroreport; 2011 Dec; 22(18):1000-4. PubMed ID: 22045259
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
    Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
    Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Change in lateralization of the P22/N30 cortical component of median nerve somatosensory evoked potentials in patients with cervical dystonia after successful treatment with botulinum toxin A.
    Kanovský P; Streitová H; Dufek J; Znojil V; Daniel P; Rektor I
    Mov Disord; 1998 Jan; 13(1):108-17. PubMed ID: 9452335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lateralization of the P22/N30 component of somatosensory evoked potentials of the median nerve in patients with cervical dystonia.
    Kanovský P; Streitová H; Dufek J; Rektor I
    Mov Disord; 1997 Jul; 12(4):553-60. PubMed ID: 9251074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myometry revealed medication-induced decrease in resting skeletal muscle stiffness in Parkinson's disease patients.
    Marusiak J; Jaskólska A; Koszewicz M; Budrewicz S; Jaskólski A
    Clin Biomech (Bristol, Avon); 2012 Jul; 27(6):632-5. PubMed ID: 22365901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
    During MJ; Kaplitt MG; Stern MB; Eidelberg D
    Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clozapine in the treatment of adverse psychiatric manifestations of long-term therapy with levodopa].
    Svetel MV; Sternić NM; Filipović SR; Vojvodić NM; Kostić VS
    Srp Arh Celok Lek; 1997; 125(7-8):203-6. PubMed ID: 9304232
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.